Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIS793 + gemcitabine + nab-paclitaxel
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
NIS793 + gemcitabine + nab-paclitaxel is a combination regimen under investigation for the first-line treatment of metastatic pancreatic ductal adenocarcinoma. NIS793 is a fully human IgG2 monoclonal antibody that targets and inhibits the transforming growth factor beta (TGF-β) pathway, which is known to regulate the tumor microenvironment and promote immune exclusion. By inhibiting TGF-β, NIS793 is expected to augment the efficacy of chemotherapy and enhance immune response. Gemcitabine is a nucleoside analog chemotherapeutic, and nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel, both broadly used as standard-of-care drugs in pancreatic cancer. The combination is being studied to improve response rates and survival by targeting both tumor proliferation and stromal immune modulation[3][8].
- Brand names
- nab-paclitaxel (Abraxane)
- Other names
- NIS793NIS-793NIS 793gemcitabinenab-paclitaxel
02
Targets
DNA polymerase familyTGFB1 (Transforming growth factor Beta-1 proprotein)RNR (Ribonucleotide reductase)TGFB3 (Transforming growth factor beta 3)TGFB2 (Transforming growth factor beta 2)Microtubule
Beyond the preview
Go deeper on NIS793 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIS793 + gemcitabine + nab-paclitaxel.